中慧生物-B：三价流感病毒亚单位疫苗的上市申请获国家药监局批准

Core Viewpoint - Zhonghui Biotech-B (02627) has received approval from the National Medical Products Administration of China for its trivalent influenza virus subunit vaccine, making it the first and only approved vaccine for all age groups in China [1] Group 1 - The vaccine is a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and a lower risk of adverse reactions [1]